The role of NNRTIs in antiretroviral combination therapy: an introduction.
In October 2000 a meeting was convened by DuPont Pharma in Scotland to discuss the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in antiretroviral therapy. The Round Table meeting focused on comparisons between efavirenz and nevirapine in clinical studies and clinical practice, and the manuscripts published in this supplement report the most salient points from the presentations and discussions.
Nelson
M
M
Chelsea and Westminster Hospital, London, UK. mark.nelson@chelwest.nhs.uk
D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D048588:Benzoxazines; D003521:Cyclopropanes; D015224:Dideoxynucleosides / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D019829:Nevirapine / Q000627:therapeutic use*; D010078:Oxazines / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D000099227:Abacavir
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D015224:Dideoxynucleosides; D019829:Nevirapine; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir; C098320:efavirenz